loading page

Safety and efficacy of catheter ablation for atrial fibrillation in abdominal solid organ (renal and hepatic) transplant recipients: a single-center pilot experience
  • +13
  • Xin Su,
  • Xin Zhao,
  • Deyong Long,
  • Caihua Sang,
  • Rong-Hui Yu,
  • Ribo Tang,
  • Rong Bai,
  • Nian Liu,
  • Chen-Xi Jiang,
  • Li Song-Nan,
  • Xue-Yuan Guo,
  • Wei Wang,
  • Rong Hu,
  • Xin Du,
  • Jian zeng Dong,
  • Chang Sheng Ma
Xin Su
Capital Medical University Affiliated Anzhen Hospital
Author Profile
Xin Zhao
Beijing An Zhen Hospital
Author Profile
Deyong Long
Capital Medical University
Author Profile
Caihua Sang
Beijing An Zhen Hospital
Author Profile
Rong-Hui Yu
Beijing An Zhen Hospital, Capital Medical University
Author Profile
Ribo Tang
Capital Medical University
Author Profile
Rong Bai
Beijing An Zhen Hospital
Author Profile
Nian Liu
Capital University of Medical Sciences
Author Profile
Chen-Xi Jiang
Beijing An Zhen Hospital, Capital Medical University
Author Profile
Li Song-Nan
Beijing Anzhen Hospital,Capital Medical University
Author Profile
Xue-Yuan Guo
Beijing An Zhen Hospital, Capital Medical University
Author Profile
Wei Wang
Beijing An Zhen Hospital
Author Profile
Rong Hu
anzhen
Author Profile
Xin Du
Capital Medical University Affiliated Anzhen Hospital
Author Profile
Jian zeng Dong
Beijing Anzhen Hospital Capital Medical University
Author Profile
Chang Sheng Ma
Beijing An Zhen Hospital
Author Profile

Abstract

Background: Atrial fibrillation (AF) is common in abdominal solid organ transplant recipients and a cause of morbidity and mortality in this population. However, the outcomes of catheter ablation (CA) in transplant recipients with AF remain unclear. This study aimed to elucidate the outcomes of CA in renal and hepatic transplant recipients. Methods and Results: Between 2015 and 2019, 14 transplant recipients (9 with kidney transplantation and 5 with liver transplantation) were enrolled from among 10,741 AF patients and underwent CA at Anzhen Hospital. Another 56 patients matched by age, sex and AF type were selected as the control group (4 controls for each transplant recipient). During a mean follow-up of 30.0±13.3 months after the initial procedure, 10 (71.4%) of the transplant patients, compared to 41 (73.2%) of the control patients, remained free from AF recurrence(P=1.000). A repeated procedure was performed in 1 transplant patient and in 6 control subjects. Consequently, 11 (78.6%) of the transplant patients, compared to 46 (82.1%) of controls, were in sinus rhythm after the repeated ablation (P=0.715). Notably, Kaplan–Meier analysis did not demonstrate any significant differences in the atrial arrhythmia-free rate after the initial and repeated procedure between the two groups. Vascular complications were identified in 1 transplant patient and 2 control subjects, while no life-threatening complications were observed in either group. There was no transient allograft dysfunction in transplant recipients after CA. Conclusion: CA is safe and effective in abdominal solid transplant recipients, and may be an optimal therapeutic strategy for this group.

Peer review status:UNDER REVIEW

23 Jun 2020Submitted to Journal of Cardiovascular Electrophysiology
23 Jun 2020Submission Checks Completed
23 Jun 2020Assigned to Editor
06 Jul 2020Reviewer(s) Assigned
31 Aug 2020Review(s) Completed, Editorial Evaluation Pending
08 Sep 2020Editorial Decision: Revise Minor
15 Sep 20201st Revision Received
15 Sep 2020Submission Checks Completed
15 Sep 2020Assigned to Editor
15 Sep 2020Reviewer(s) Assigned